# FDA Approves New Drug Application for Apotex Apotex received FDA approval for NDA220837 on May 1, 2026, positioning the Canadian pharmaceutical manufacturer to capture additional market share in a competitive therapeutic segment. The approval strengthens Apotex's product portfolio and may enhance the company's revenue growth trajectory in the coming fiscal year.